{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:26:47Z","timestamp":1790771207915,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Radiotherapy (RT) following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) reduces ipsilateral breast event rates in clinical trials. This study assessed the impact of DCIS treatment on a 20-year risk of ipsilateral DCIS (iDCIS) and ipsilateral invasive breast cancer (iIBC) in a population-based cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The cohort comprised all women diagnosed with DCIS in the Netherlands during 1989\u20132004 with follow-up until 2017. Cumulative incidence of iDCIS and iIBC following BCS and BCS\u2009+\u2009RT were assessed. Associations of DCIS treatment with iDCIS and iIBC risk were estimated in multivariable Cox models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 20-year cumulative incidence of any ipsilateral breast event was 30.6% (95% confidence interval (CI): 28.9\u201332.6) after BCS compared to 18.2% (95% CI 16.3\u201320.3) following BCS\u2009\u2009+\u2009\u2009RT. Women treated with BCS compared to BCS\u2009+\u2009RT had higher risk of developing iDCIS and iIBC within 5 years after DCIS diagnosis (for iDCIS: hazard ratio (HR)<jats:sub>age\u2009&lt;\u200950<\/jats:sub> 3.2 (95% CI 1.6\u20136.6); HR<jats:sub>age\u2009\u2265\u200950<\/jats:sub> 3.6 (95% CI 2.6\u20134.8) and for iIBC: HR<jats:sub>age&lt;50<\/jats:sub> 2.1 (95% CI 1.4\u20133.2); HR<jats:sub>age\u2009\u2265\u200950<\/jats:sub> 4.3 (95% CI 3.0\u20136.0)). After 10 years, the risk of iDCIS and iIBC no longer differed for BCS versus BCS\u2009+\u2009RT (for iDCIS: HR<jats:sub>age\u2009&lt;\u200950<\/jats:sub> 0.7 (95% CI 0.3\u20131.5); HR<jats:sub>age\u2009\u2265\u200950<\/jats:sub> 0.7 (95% CI 0.4\u20131.3) and for iIBC: HR<jats:sub>age\u2009&lt;\u200950<\/jats:sub> 0.6 (95% CI 0.4\u20130.9); HR<jats:sub>age\u2009\u2265\u200950<\/jats:sub> 1.2 (95% CI 0.9\u20131.6)).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>RT is associated with lower iDCIS and iIBC risk up to 10 years after BCS, but this effect wanes thereafter.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01496-6","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T12:10:57Z","timestamp":1629288657000},"page":"1443-1449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast"],"prefix":"10.1038","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-239X","authenticated-orcid":false,"given":"Maartje","family":"van Seijen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-4935","authenticated-orcid":false,"given":"Esther H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Giardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-509X","authenticated-orcid":false,"given":"Linda","family":"de Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte E.","family":"Elshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-4111","authenticated-orcid":false,"given":"Elinor","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Ryser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula H. M.","family":"Elkhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Grand Challenge PRECISION Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-2676","authenticated-orcid":false,"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"1496_CR1","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL). DCIS incidence trends over time. The Netherlands. https:\/\/iknl.nl\/nkr."},{"key":"1496_CR2","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975\u20132017. Bethesda: National Cancer Institute; 2017. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"1496_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst. 2019;111:1\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30759222\/.","journal-title":"J Natl Cancer Inst"},{"key":"1496_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97:135\u201344.","journal-title":"Breast Cancer Res Treat"},{"key":"1496_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441\u201352. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9469327.","journal-title":"J Clin Oncol"},{"key":"1496_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"C Correa","year":"2010","unstructured":"Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162\u201377.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1496_CR7","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","volume":"24","author":"N Bijker","year":"2006","unstructured":"Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien J-P, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853\u2014a study by the EORTC Breast Cancer Cooperative Group and. J Clin Oncol. 2006;24:3381\u20137. http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.06.1366.","journal-title":"J Clin Oncol"},{"key":"1496_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/02841860600681569","volume":"45","author":"SO Emdin","year":"2006","unstructured":"Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson L-GG, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45:536\u201343. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16864166.","journal-title":"Acta Oncol"},{"key":"1496_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0140-6736(03)13859-7","volume":"362","author":"J Houghton","year":"2003","unstructured":"Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95\u2013102. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12867108.","journal-title":"Lancet"},{"key":"1496_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-016-3973-y","volume":"159","author":"LE Elshof","year":"2016","unstructured":"Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res Treat. 2016;159:553\u201363.","journal-title":"Breast Cancer Res Treat."},{"key":"1496_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354. http:\/\/projecteuclid.org\/euclid.aos\/1176350951.","journal-title":"Ann Stat"},{"key":"1496_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/atm.2016.08.62","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Geskus RB, Kattan MW, Zhang H, Liu T. Nomogram for survival analysis in the presence of competing risks. Ann Transl Med. 2017;5:47.","journal-title":"Ann Transl Med"},{"key":"1496_CR13","unstructured":"R Core Team. R: a language and environment for statistical computing. 2018. https:\/\/www.r-project.org."},{"key":"1496_CR14","doi-asserted-by":"publisher","unstructured":"Groen EJ, Hudecek J, Mulder L, van Seijen M, Almekinders MM, Alexov S, et al. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Res Treat. 2020;183:759\u201370. https:\/\/doi.org\/10.1007\/s10549-020-05816-x.","DOI":"10.1007\/s10549-020-05816-x"},{"key":"1496_CR15","doi-asserted-by":"crossref","unstructured":"van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers CCHJ, Overbeek LIH, Deckers IAG. Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat. 2018. http:\/\/link.springer.com\/10.1007\/s10549-018-05082-y.","DOI":"10.1007\/s10549-018-05082-y"},{"key":"1496_CR16","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","volume":"32","author":"F W\u00e4rnberg","year":"2014","unstructured":"W\u00e4rnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32:3613\u20138.","journal-title":"J Clin Oncol"},{"key":"1496_CR17","doi-asserted-by":"publisher","unstructured":"Sprague BL, Vacek PM, Herschorn SD, James TA, Geller BM, Trentham-Dietz A, et al. Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort. Breast Cancer Res Treat. 2018;174:0. https:\/\/doi.org\/10.1007\/s10549-018-5048-8.","DOI":"10.1007\/s10549-018-5048-8"},{"key":"1496_CR18","first-page":"313","volume":"92","author":"FM Waldman","year":"2000","unstructured":"Waldman FM, Devries S, Chew KL, Ii DHM, Ljung B. Chromosomal alterations in ductal carcinomas in situ. Cancer. 2000;92:313\u201320.","journal-title":"Cancer"},{"key":"1496_CR19","doi-asserted-by":"publisher","unstructured":"Shah V, Megalios A, Shami R, Sridharan M, Salinas de Souza C, Kumar T, et al. Genomic analysis of paired DCIS and subsequent recurrence to assess clonal relatedness in screen-detected DCIS[abstract]. Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10\u201314; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2020;80(4 Suppl):Abstract nr P4-07-04. https:\/\/doi.org\/10.1158\/1538-7445.","DOI":"10.1158\/1538-7445"},{"key":"1496_CR20","doi-asserted-by":"publisher","unstructured":"van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121:285\u201392. https:\/\/doi.org\/10.1038\/s41416-019-0478-6.","DOI":"10.1038\/s41416-019-0478-6"},{"key":"1496_CR21","doi-asserted-by":"publisher","unstructured":"Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project On behalf of the Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias) 1. Eur J Cancer. 2018;101:210\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.027.","DOI":"10.1016\/j.ejca.2018.06.027"},{"key":"1496_CR22","doi-asserted-by":"publisher","first-page":"m1570","DOI":"10.1136\/bmj.m1570","volume":"369","author":"GS Mannu","year":"2020","unstructured":"Mannu GS, Wang Z, Broggio J, Charman J, Cheung S, Kearins O, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ. 2020;369:m1570. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32461218.","journal-title":"BMJ"},{"key":"1496_CR23","doi-asserted-by":"publisher","unstructured":"Shaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. Br J Cancer. 2020:1\u20139. https:\/\/doi.org\/10.1038\/s41416-020-01152-5.","DOI":"10.1038\/s41416-020-01152-5"},{"key":"1496_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10549-019-05377-8","volume":"178","author":"E Rakovitch","year":"2019","unstructured":"Rakovitch E, Sutradhar R, Hallett M, Thompson AM, Gu S, Dumeaux V, et al. The time-varying effect of radiotherapy after breast-conserving surgery for DCIS. Breast Cancer Res Treat. 2019;178:221\u201330. http:\/\/link.springer.com\/10.1007\/s10549-019-05377-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1496_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature13600","volume":"512","author":"Y Wang","year":"2014","unstructured":"Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155\u201360.","journal-title":"Nature"},{"key":"1496_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","volume":"44","author":"D Akdeniz","year":"2019","unstructured":"Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, van den Broek AJ, et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019;44:1\u201314.","journal-title":"Breast"},{"key":"1496_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.20886","volume":"103","author":"LJ Solin","year":"2005","unstructured":"Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137\u201346.","journal-title":"Cancer"},{"key":"1496_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw256","volume":"109","author":"E Rakovitch","year":"2017","unstructured":"Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Baehner FL, Miller DP, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. J Natl Cancer Inst. 2017;109:1\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1496_CR29","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24:5895\u2013901.","journal-title":"Clin Cancer Res"},{"key":"1496_CR30","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51:2296\u2013303.","journal-title":"Eur J Cancer"},{"key":"1496_CR31","doi-asserted-by":"publisher","unstructured":"Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study. Eur J Cancer. 2015;51:1497\u2013510. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008.","DOI":"10.1016\/j.ejca.2015.05.008"},{"key":"1496_CR32","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30862637.","journal-title":"BMJ Open"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01496-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01496-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01496-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:02:53Z","timestamp":1636416173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01496-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,11,9]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01496-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Central Committee on Research involving Human Subjects determined that this study did not require approval from an ethics committee. The privacy review board of the NCR approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}